Will Regeneron (REGN) Beat Estimates Again in Its Next Earnings Report?Zacks Investment Research • 10/12/26
Pasatru™ (garetosmab-grts) Demonstrates Zero New Heterotopic Ossification (HO) Lesions in Adult Fibrodysplasia Ossificans Progressiva (FOP) Patients During OPTIMA Trial ExtensionGlobeNewsWire • 10/12/26
Regeneron Showcases Advances in Care Across Several Cancers and Cancer-associated Complications at ESMO 2026GlobeNewsWire • 10/06/26
Regeneron Pharmaceuticals, Inc. (REGN) Discusses Expanded Collaboration on Next-Generation Long-Acting Immunology Antibodies TranscriptSeeking Alpha • 10/01/26
Ubamatamab (MUC16xCD3) Shows a High Rate of Durable Responses in Initial Study of Patients with Advanced Low-Grade Serous Ovarian Cancer (LGSOC)GlobeNewsWire • 10/01/26
Phase 2 COURAGE Trial Confirms Trevogrumab Prevents Lean Mass and Muscle Loss During GLP-1 Receptor Agonist-induced Weight LossGlobeNewsWire • 10/01/26
Lilly vs. Novo: Inside the Milan EASD Showdown and the ETFs Poised to WinZacks Investment Research • 10/01/26
Regeneron and Sanofi Expand Global Alliance with Multiple Next-Generation, Long-Acting Immunology AntibodiesGlobeNewsWire • 10/01/26
Press Release: Sanofi and Regeneron expand global Alliance with multiple next-generation, long-acting immunology antibodiesGlobeNewsWire • 10/01/26
Regeneron to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on October 30, 2026GlobeNewsWire • 09/24/26